**Option Care Health Approves $500 Million Stock Repurchase Program**

On January 10, 2025, Option Care Health, Inc. announced the approval of a new $500 million stock repurchase program. The Board of Directors of the company passed this new initiative, which has no specified expiration date. The program allows for the repurchase of shares through various means such as open market purchases, privately negotiated transactions, block trades, or structured share repurchase programs.

The decision to repurchase shares under this program will be subject to a range of factors including market conditions, regulatory requirements, and other corporate considerations as determined by the company’s management. This move aims to enhance shareholder value and align with the company’s strategic objectives.

In other recent disclosures, the company furnished a press release concerning its preliminary financial results for the three and twelve months ending on December 31, 2024, along with financial expectations for the full year 2025. Additionally, as part of its participation at the 43rd Annual J.P. Morgan Healthcare Conference, a presentation was also made available.

Option Care Health emphasizes that the information included in the filing shall not be considered as filed for regulatory purposes and should not be incorporated by reference in any securities filing unless expressly indicated. The company remains committed to its financial transparency and strategic initiatives, focusing on sustainable growth and delivering value to its stakeholders.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Option Care Health’s 8K filing here.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.